莱博雷生2024年的价格是多少钱一盒?

Author: Medicalhalo

Release time: 2025-10-19 11:44:20

The price of Lebrasin in 2024 is currently known to be between US$77 and US$165. Different dosage forms will lead to different drug prices.

Leboresen is an orexin receptor antagonist developed by Japan's Eisai. It is used to treat insomnia in adults. It can provide patients with faster sleep onset and better sleep maintenance. At present, we know that the price of the Japanese version of Lebrasin is approximately as follows:

For 10 mg, one box costs about 165 US dollars;

For 5 mg, one box costs about 117 US dollars;

For 2.5 mg, one box costs about $77.

Drugs have different specifications, dosage forms, and prices. It is recommended that patients take the medication under the guidance of a doctor. If there is intolerance, contact the doctor in time for symptomatic treatment.

Purchase channels for Lebrasei

As of February 4, 2024, it has not been launched in mainland China. The purchasing channels currently known are as follows:

1. Go to Japan to buy

Patients can apply for documents and go to Japan to buy, see a doctor in a local hospital, get a prescription from a doctor, buy the drug under the guidance of the doctor, and understand the use of the drug, but they need to find a regular hospital pharmacy to avoid being cheated.

2. Help from friends

If you have relatives and friends in the marketed area, you can also ask them to help buy the medicine and take it home, but you need to distinguish the quality and safety of the medicine.

3. Help from overseas medical service institutions

Patients can also search for domestic professional overseas medical service institutions online. Qualified and formal medical institutions can help patients obtain drugs, sign contracts, guarantee that they are genuine, and mail the drugs to their homes, saving patients the trouble of traveling far to purchase drugs, and are more cost-effective.

Pharmacokinetics of Lebraxen

The bioavailability of Lebraxen is good, at least 87%. It takes 1 to 3 hours for Leborex to reach peak levels. The study found that high-fat and high-calorie meals delayed the time to peak levels by 2 hours. Its in vitro plasma protein binding is 94%. Leborexan is mainly metabolized by CYP3A4 and to a lesser extent by CYP3A5. The "effective" half-life of leborexan is 17 to 19 hours, and its ultimate elimination half-life is 55 hours. The drug was excreted in the feces (57%) and to a lesser extent in the urine (29%).

Peak normalized concentrations (% of C max) of the orexin receptor antagonists suvorexant (SUV; 20 mg, suvorexant) and leborexant (LEM; 10 mg) at steady-state dosing in humans.

Although leborexant has a longer terminal elimination half-life than suvorexant, it appears to be cleared more rapidly than suvorexant during the early stages of elimination. Additionally, leborexant dissociates from orexin receptors more rapidly than suvorexant. These differences may result in relatively fewer next-day effects, such as daytime drowsiness caused by leborexan.

Effects of leboresen

Efficacy and safety results in subjects with insomnia who received leboresen for up to 12 months in Study E2006-G000-303 (Study 303; SUNRISE-2). Study 303 was a 12-month, global, multicenter, randomized, double-blind, parallel-group Phase 3 study divided into two treatment periods.

In treatment period 1 (first 6 months), subjects (n = 949) were randomly assigned to receive daily placebo, 5 mg leborexan (LEM5), or 10 mg leborexan (LEM10). In treatment period 2 (last 6 months), placebo subjects were rerandomized to LEM5 or LEM10, while subjects randomized to leborexan continued to receive their assigned treatment (LEM5, n = 251; LEM10, n = 226).

Results

For all sleep parameters, significant effects of LEM5 and LEM10 compared with placebo were observed at 6 months and maintained at 12 months in subjects who received continuous treatment for 12 months. After stopping the drug, no subjects in the two groups experienced rebound insomnia or withdrawal symptoms.

Conclusion

Compared with placebo, LEM5 and LEM10 had significant effects on sleep initiation and sleep maintenance. Importantly, the effect of leborexan was still effective after 12 months, indicating that leborexan can bring long-term effects to patients with insomnia.